Skip to main content
VulnerabilityPublished

CVE-2026-127412: Oracle VM VirtualBox · Easily exploitable vulnerability allows high privileged attacker with logon to the infrastructure

Affects Oracle VM VirtualBoxSource CVE Database V5

0
Compare

Not known to be exploited · CVSS 6.7 Medium.

Data as of 17 Nov 2026, 22:22 UTC

CVSS 3.1 base score
6.7Medium
How severe the flaw is on the 0–10 CVSS scale.

Thin evidence

One scorer or none
CVSS scores by source
CNA (oracle)CVSS 3.16.7
CVSS:3.1/AV:L/AC:L/PR:H/UI:N/S:C/C:L/I:N/A:H

Exploitation evidence

  1. Disclosed: evidence found.

    CVE published 17 Nov 2026

  2. Detectable: no evidence on record.

    No public nuclei template indexed

  3. Weaponized: no evidence on record.

    No public exploit code indexed in Metasploit or Exploit-DB

  4. Exploited in the wild: no evidence on record.

    Not in CISA KEV and no source reports exploitation

  5. Observed by OffSeq Mirage: no evidence on record.

    No attack traffic recorded by OffSeq Mirage sensors

A missing step is not evidence of safety. Sources: cve.org (opens in a new tab), the Metasploit, Exploit-DB and nuclei-templates index as of 17 Nov 2026.

What to do

Affected software

ProductAffectedFixed in
Oracle CorporationOracle VM VirtualBoxAffected
  • =7.2.22
Fixed in–

AI-suggested

Oracle has released security patches as part of the November 2026 Critical Security Patch Update that address this vulnerability. Customers are strongly advised to apply the available patches promptly to mitigate the risk. No other specific mitigations or workarounds are indicated in the vendor advisory. Maintaining up-to-date patched versions is the recommended course of action.

Description

CVE-2026-127412 is a vulnerability in Oracle VM VirtualBox version 7.2.22 that allows a high privileged attacker with logon access to the infrastructure to cause a denial of service (hang or crash) and unauthorized read access to some data. The vulnerability affects the core component of Oracle VM VirtualBox and may impact additional products. It has a CVSS 3.1 base score of 6.7, indicating medium severity with confidentiality and availability impacts.

References

Community reviews

Loading reviews…